首页> 外国专利> USES OF SOLUBLE LIGANDS THAT INTERACT WITH GP39, CD40, B7, CTLA4 AND/OR CD28 FOR PREPARING PHARMACEUTICAL COMPOSITIONS

USES OF SOLUBLE LIGANDS THAT INTERACT WITH GP39, CD40, B7, CTLA4 AND/OR CD28 FOR PREPARING PHARMACEUTICAL COMPOSITIONS

机译:与GP39,CD40,B7,CTLA4和/或CD28相互作用的可溶性配体在制备药物组合物中的用途

摘要

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
机译:本发明提供了一种抑制免疫应答的方法和一种抑制移植组织排斥的方法。该方法包括防止选自gp39和CD40抗原的细胞上的内源分子结合其内源配体,以及阻止选自CTLA4,CD28和B7抗原的细胞上的内源分子结合其内源。配体。防止此类分子结合其配体从而阻断了两个独立的信号途径并抑制了免疫反应,导致移植的组织排斥。

著录项

  • 公开/公告号IL125928A

    专利类型

  • 公开/公告日2002-11-10

    原文格式PDF

  • 申请/专利权人 BRISTOL-MYERS SQUIBB COMPANY;EMORY UNIVERSITY;

    申请/专利号IL19970125928

  • 发明设计人

    申请日1997-03-20

  • 分类号A61K39/395;A61K38/17;

  • 国家 IL

  • 入库时间 2022-08-22 00:44:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号